MedTrace Logo

Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

NCT00823849 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-03-27

No results posted yet for this study

Summary

1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker
2. To evaluate the safety of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker

Conditions

Interventions

DRUG

Cilostazol

From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.

DRUG

Probucol

250 mg Bid, PO after breakfast and dinner.

DRUG

Cilostazol+Probucol

OTHER

Control Group

Routine treatment

Sponsors & Collaborators

  • Otsuka Beijing Research Institute

    lead INDUSTRY

Principal Investigators

  • Xiaohui Guo, M.D. · No 1 Hospital of Peking University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-08-31
Completion
2010-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823849 on ClinicalTrials.gov